Cargando…
Development and Evaluation of a Physiologically Based Pharmacokinetic Model of Labetalol in Healthy and Diseased Populations
Labetalol is a drug that exhibits both alpha and beta-adrenergic receptor-blocking properties. The American Heart Association/American Stroke Association (AHA/ASA) has recommended labetalol as an initial treatment option for the management of severe hypertension. The physiologically based pharmacoki...
Autores principales: | Hafsa, Hafsa, Zamir, Ammara, Rasool, Muhammad Fawad, Imran, Imran, Saeed, Hamid, Ahmad, Tanveer, Alsanea, Sary, Alshamrani, Ali A., Alruwaili, Abdullah H., Alqahtani, Faleh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696499/ https://www.ncbi.nlm.nih.gov/pubmed/36365181 http://dx.doi.org/10.3390/pharmaceutics14112362 |
Ejemplares similares
-
A physiologically based pharmacokinetic model of cefepime to predict its pharmacokinetics in healthy, pediatric and disease populations
por: Talha Zahid, Muhammad, et al.
Publicado: (2023) -
Physiologically
Based Pharmacokinetic
Model To Predict Metoprolol Disposition in Healthy and Disease Populations
por: Zamir, Ammara, et al.
Publicado: (2023) -
Predicting Hydroxychloroquine Clearance in Healthy and Diseased Populations Using a Physiologically Based Pharmacokinetic Approach
por: Alqahtani, Faleh, et al.
Publicado: (2023) -
Application of a physiologically based pharmacokinetic model in predicting captopril disposition in children with chronic kidney disease
por: Khalid, Sundus, et al.
Publicado: (2023) -
Development and Evaluation of a Physiologically Based Pharmacokinetic Model for Predicting Haloperidol Exposure in Healthy and Disease Populations
por: Alasmari, Mohammed S., et al.
Publicado: (2022)